Novavax Eliminates COO Position, Trizzino to Consult

Novavax ( (NVAX) ) has issued an update.

On May 27, 2025, Novavax, Inc. announced the elimination of the Chief Operating Officer position, resulting in the termination of John Trizzino’s employment effective June 20, 2025. Following his departure, Mr. Trizzino will continue to provide consulting services to the company until December 31, 2025, under a new consulting agreement. The separation agreement includes a lump sum payment and COBRA premium coverage for Mr. Trizzino, while the consulting agreement ensures a monthly fee and continued vesting of his equity awards.

The most recent analyst rating on (NVAX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.

Spark’s Take on NVAX Stock

According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.

Novavax’s stock shows potential with strong revenue growth and profitability improvements, supported by strategic partnerships and recent FDA approval. However, financial instability, regulatory challenges, and market penetration issues weigh on the stock. Valuation metrics suggest upside potential, yet technical indicators advise caution.

To see Spark’s full report on NVAX stock, click here.

More about Novavax

Average Trading Volume: 8,364,141

Technical Sentiment Signal: Sell

Current Market Cap: $1.17B

See more data about NVAX stock on TipRanks’ Stock Analysis page.